Bio-Techne Corporation (TECH) Stock Price: $71.00+0.30 (+0.42%)
At close: Jun 26, 2026, 4:00 PM ET
The closing share price for Bio-Techne Corporation (TECH) stock was $71.00 for Friday, June 26, 2026, up 0.42% on the day.
Longer view (total return, dividends reinvested): past 12 months +35.3% · 3-year avg -2.1%/yr · 5-year avg -7.8%/yr
TECH Price Chart
TECH Key Metrics
See All MetricsLAST CLOSE PRICE
$71.00
52-WEEK RANGE
$43.20 - $72.16
BETA
1.36
% FROM 52W HIGH
-1.61%
MARKET CAP
$11.12B
DIVIDEND YIELD
0.45%
PE RATIO
trailing TTM
102.90
PE RATIO (FWD)
next-FY estimate
34.43
P/B RATIO
5.34
DEBT / EQUITY
0.23
REVENUE TTM
$1.21B
NET INCOME TTM
$109.57M
NET PROFIT MARGIN TTM
9.05%
TTM TOTAL RETURN
+35.31%
3Y TOTAL RETURN
-2.07%
5Y TOTAL RETURN
-7.83%
TECH Revenue by Segment
How TECH’s revenue breaks down across its reported segments in the latest reported fiscal year.
By product / business (FY 2025)
- Consumables$972.29M79.7%
- Instruments$112.09M9.2%
- Royalty$23.69M1.9%
- Unallocated$111.57M9.1%
By geography (FY 2025)
- U S$683.23M56.0%
- Europe$266.31M21.8%
- C N$100.46M8.2%
- APAC, excluding Greater China$77.26M6.3%
- United Kingdom$54.83M4.5%
- Rest Of World$37.55M3.1%
TECH Earnings Preview
Next Earnings Date
Aug 5, 2026
39 days away
EPS Estimate
0.53
Revenue Est.
$314.40M
Last Quarter Results
EPS
$0.53
vs Estimate
$0.53
Revenue
$311.42M
vs Estimate
$316.11M
TECH Analyst Ratings
Consensus Rating
Based on 12 analysts
Average Price Target
$65.75
-7.4% downside
Low
$50.00
Current
$71.00
High
$75.00
TECH Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q3 2026 | $0.43 | $0.44 | $0.46 | 5 |
| Q4 2026 | $0.47 | $0.48 | $0.49 | 1 |
| Q1 2027 | $0.55 | $0.56 | $0.58 | 1 |
| Q2 2027 | $0.56 | $0.57 | $0.58 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $1.94 | $2.06 | $2.15 | 9 |
| FY 2028 | $2.18 | $2.33 | $2.50 | 3 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q3 2026 | $286.59M | $291.39M | $300.78M | 6 |
| Q4 2026 | $303.63M | $307.95M | $313.51M | 5 |
| Q1 2027 | $323.76M | $328.38M | $334.30M | 3 |
| Q2 2027 | $328.05M | $332.72M | $338.73M | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $1.23B | $1.26B | $1.28B | 10 |
| FY 2028 | $1.38B | $1.38B | $1.38B | 9 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcareTECH Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TECH | $11.12B | $71.00 | +0.42% | +35.31% | -7.83% | +10.47% | — |
| 2PODD | $10.86B | $153.82 | +3.32% | -49.48% | -10.86% | +18.55% | vs TECH |
| 3BAX | $11.38B | $22.04 | +2.27% | -27.14% | -21.56% | -5.18% | vs TECH |
| 4MOH | $11.79B | $216.04 | +7.23% | -22.24% | -2.33% | +16.23% | vs TECH |
| 5WBA | $10.37B | $11.98 | +0.00% | +31.43% | -16.99% | -14.92% | vs TECH |
| 6CRL | $10.20B | $212.71 | +5.25% | +39.57% | -10.47% | +10.16% | vs TECH |
TECH Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman